Literature DB >> 12445674

Estrogens in female thyroid cancer: alteration of urinary profiles in pre- and post-operative cases.

Seon Hwa Lee1, Kyung Mee Kim, Byung Hwa Jung, Woung Youn Chung, Cheong Soo Park, Bong Chul Chung.   

Abstract

To evaluate the potential effect of estrogens in premenopausal female thyroid cancer, the concentrations of 14 estrogens were quantitatively determined in the urine of pre- and post-operative patients with thyroid papillary cancer (18 patients case, 26 approximately 54 years) and normal female subjects (20 cases, 31 approximately 52 years). The highly sensitive gas chromatography-mass spectrometry-selected ion-monitoring method was used for estrogens analysis. And an estrogen-oxidative metabolism and 16alpha-hydroxyestrone to 2-hydroxyestrone (16alpha-OH E1/2-OH E1) which is the two primary and competing site of estrogen-oxidation, were determined. Catechol estrogens, including 2-OH E1, were also increased without significant changes of the other estrogen metabolites in pre-operative patients with thyroid papillary cancer compared with normal subjects. The lowest mean value of 16alpha-OH E1/2-OH E1 was remarked in pre-operative patients, and it was significantly different from the ratio of post-operative cases. As a result, it is suggested that the increase of 2-hydroxylation in estrogen metabolism may have a significant association with female thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12445674     DOI: 10.1016/s0304-3835(02)00514-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  2 in total

1.  A novel GC-MS method in urinary estrogen analysis from postmenopausal women with osteoporosis.

Authors:  Ju-Yeon Moon; Kwang Joon Kim; Myeong Hee Moon; Bong Chul Chung; Man Ho Choi
Journal:  J Lipid Res       Date:  2011-05-21       Impact factor: 5.922

Review 2.  Oncometabolites as biomarkers in thyroid cancer: a systematic review.

Authors:  Fatemeh Khatami; Moloud Payab; Masoumeh Sarvari; Kambiz Gilany; Bagher Larijani; Babak Arjmand; Seyed Mohammad Tavangar
Journal:  Cancer Manag Res       Date:  2019-02-25       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.